Connect With Us
Describe your need or issue with us and a Kinexum representative will be in touch with you shortly to discuss how we might be able to assist you.
Thomas Seoh is an entrepreneur/executive who has held senior leadership positions in public and private, pharmaceutical, biotech, and medical device companies for three decades. After practicing corporate law in New York and London and serving as General Counsel for several companies, including the ICN Pharmaceuticals group in Costa Mesa, he joined Guilford Pharmaceuticals in Baltimore, which developed and commercialized GLIADEL® wafer for glioblastoma multiforme and developed the propofol pro-drug LUSEDRA® and small molecules for Parkinson’s disease. Thomas began as Guilford’s VP, General Counsel and Secretary, and later served as SVP Corporate and Commercial Development. He was then CEO of venture-backed Faust Pharmaceuticals in Strasbourg, France, developing a repurposed compound in Phase II for Parkinson’s patients, a re-positioned molecule for Duchenne muscular dystrophy and a GPCR drug discovery platform. He serves on the Board of a startup therapeutic company targeting mitochondrial ion channels and transporters for ‘metabesic’ and cancer indications, and previously served on the Board of a Cedars Sinai spin-out with an ex vivo liver dialysis device in clinical development. Additionally, he previously served as President or CEO of medical device companies developing a novel mechanical thrombectomy device for Deep Vein Thrombosis and stroke, a state-of-the-art neurocatheter, and the first plant-based skin substitute wound dressing. He is a former member of the Hopkins Alliance, an industry-faculty advisory board at Johns Hopkins School of Medicine, and an industry advisory board at University of Maryland Baltimore County. As EVP of the not-for-profit Kitalys Institute, he has been an organizer of the acclaimed Targeting Metabesity conferences and multiple webinars on topics such as biological clocks and other biomarkers of aging for regulatory development, development of therapeutics targeting mitochondria, molecular and evolutionary bases of exercise as geroprotection and the Dog Aging Project. Thomas holds an AB in Philosophy and History and a JD from Harvard University.